On 10 23, Huisheng Bio announced in its third-quarter results that revenue for the first three quarters of 2026 was approximately 12.85 hundred million yuan, up 2% year over year; net profit attributable to shareholders of the listed company was approximately 2.59 hundred million yuan, up 37.75% year over year; and basic earnings per share were 1.2822 yuan, up 26.52% year over year.
On the same day, Huisheng Bio stated in its investor relations communication that, in the first three quarters of 2026, all of the company’s business segments—poultry, pets, aquatic products, and ruminants—showed good growth. Sales revenue in the poultry, pets, and ruminants segments each increased by more than 30% year over year.
Notably, Huisheng Bio recently said in an investor relations communication that construction of its Xinjiang Synthetic Biology Intelligent Manufacturing Project is progressing smoothly and is expected to commence production in the first half of next year. The company has accumulated substantial production experience in microbial fermentation, which is conducive to the smooth implementation of the project, although actual capacity utilization is also closely related to market demand. The company is actively developing domestic and international market channels and advancing related work, including the U.S. DMF filing for the active pharmaceutical ingredient and the application for European CEP certification, while also coordinating with the FDA on subsequent review matters.